# Alexander E. Perl

Source: https://onco.cc/people/alexander-perl/  
OnCo record `alexander-perl` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led ADMIRAL, which made gilteritinib the standard for relapsed FLT3-mutant AML.

## Summary

Alexander Perl was principal investigator of ADMIRAL, which showed the FLT3 inhibitor gilteritinib doubles survival versus salvage chemotherapy in relapsed or refractory FLT3-mutant AML, the first randomised trial to establish single-agent targeted therapy in the disease. He led the earlier phase 1/2 gilteritinib study and studies of resistance to FLT3 inhibition. He leads AML clinical research at Penn.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: aml; flt3; targeted-therapy
- Role: Professor of Medicine, Abramson Cancer Center, University of Pennsylvania
- Specialisms: Acute myeloid leukaemia; FLT3 inhibitors; Relapsed AML; Resistance mechanisms

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Perl%20AE%5BAuthor%5D%20gilteritinib

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [FLT3](https://onco.cc/targets/flt3/)
- institutions: [Abramson Cancer Center, University of Pennsylvania](https://onco.cc/institutions/penn-abramson/)
- trials: [ADMIRAL](https://onco.cc/trials/admiral/)
- key papers: [ADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia](https://onco.cc/key-papers/paper-admiral-gilteritinib-flt3-nejm-2019/)

---
JSON: https://onco.cc/api/v1/entities/alexander-perl.json